Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1758-2652

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir ; volume:13 ; number:4 ; day:8 ; month:11 ; year:2010 ; pages:1 ; date:12.2010
Journal of the International AIDS Society / International AIDS Society ; 13, Heft 4 (8.11.2010), 1, 12.2010

Creator: Nozza, S.

Contributor: Galli, L.
Di Pietro, M.
Mazzotta, F.
Canducci, F.
Pogliaghi, M.
Chiappetta, S.
Galli, A.
Rusconi, V.
Salpietro, S.
Tambussi, G.
Lazzarin, A.
SpringerLink (Online service)

DOI: 10.1186/1758-2652-13-S4-P5

URN: urn:nbn:de:1111-2016052060212

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:49 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Nozza, S.
Galli, L.
Di Pietro, M.
Mazzotta, F.
Canducci, F.
Pogliaghi, M.
Chiappetta, S.
Galli, A.
Rusconi, V.
Salpietro, S.
Tambussi, G.
Lazzarin, A.
SpringerLink (Online service)

Other Objects (12)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

The use of a darunavir/ritonavir once-daily regimen in two pregnant women

O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification

Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens

Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation

Once-daily regimens were associated with a higher rate of self-chosen discontinuations

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

The use of a darunavir/ritonavir once-daily regimen in two pregnant women

O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification

Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens

Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation

Once-daily regimens were associated with a higher rate of self-chosen discontinuations

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

The use of a darunavir/ritonavir once-daily regimen in two pregnant women

O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification

Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens

Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation

Once-daily regimens were associated with a higher rate of self-chosen discontinuations

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

The use of a darunavir/ritonavir once-daily regimen in two pregnant women

O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification

Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens

Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation

Once-daily regimens were associated with a higher rate of self-chosen discontinuations

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

The use of a darunavir/ritonavir once-daily regimen in two pregnant women

O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification

Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens

Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation

Once-daily regimens were associated with a higher rate of self-chosen discontinuations

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

The use of a darunavir/ritonavir once-daily regimen in two pregnant women

O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification

Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens

Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation

Once-daily regimens were associated with a higher rate of self-chosen discontinuations

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Related objects

Reset password